Sustained immune tolerance induction in enzyme replacement therapy–treated CRIM-negative patients with infantile Pompe disease

JCI Insight

Volumn 2, Issue 16, 2017, Pages

  Kazi, Zoheb B ^a   Desai, Ankit K ^a   Berrier, Kathryn L ^a   Bradley Troxler, R ^b   Wang, Raymond Y ^c   Abdul Rahman, Omar A ^d   Tanpaiboon, Pranoot ^e   Mendelsohn, Nancy J ^f   Herskovitz, Eli ^g   Kronn, David ^h   Inbar Feigenberg, Michal ⁱ   Ward Melver, Catherine ^j   Polan, Michelle ^j   Gupta, Punita ^k   Rosenberg, Amy S ^l   Kishnani, Priya S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

^d UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^e CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^f CHILDREN S HOSPITALS AND CLINICS OF MINNESOTA   (United States)

^g BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^h NEW YORK MEDICAL COLLEGE   (United States)

ⁱ HOSPITAL FOR SICK CHILDREN   (Canada)

^j AKRON CHILDREN'S HOSPITAL   (United States)

^k ST JOSEPH S REGIONAL MEDICAL CENTER   (United States)

^l CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85041312127     PISSN: None     EISSN: 23793708     Source Type: Journal    
DOI: 10.1172/JCI.INSIGHT.94328     Document Type: Article

References (43)

1. Porter S. Human immune response to recombinant human proteins. J Pharm Sci. 2001;90(1):1–11.
2. Banugaria SG, et al. The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease. Genet Med. 2011;13(8):729–736.
3. Baert F, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med. 2003;348(7):601–608.
4. Wadhwa M, et al. Immunogenicity of granulocyte-macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF. Clin Cancer Res. 1999;5(6):1353–1361.
5. Bertolotto A. Neutralizing antibodies to interferon beta: implications for the management of multiple sclerosis. Curr Opin Neurol. 2004;17(3):241–246.
6. Hjelm Skog AL, et al. Alteration of interleukin 2 (IL-2) pharmacokinetics and function by IL-2 antibodies induced after treatment of colorectal carcinoma patients with a combination of monoclonal antibody 17-1A, granulocyte macrophage colony-stimulating factor, and IL-2. Clin Cancer Res. 2001;7(5):1163–1170.
7. van Gelder CM, Hoogeveen-Westerveld M, Kroos MA, Plug I, van der Ploeg AT, Reuser AJ. Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease. J Inherit Metab Dis. 2015;38(2):305–314.
8. Kishnani PS, et al. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr. 2006;148(5):671–676.
9. Nicolino M, et al. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet Med. 2009;11(3):210–219.
10. Kishnani PS, et al. Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr. 2006;149(1):89–97.
11. Kishnani PS, et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology. 2007;68(2):99–109.
12. Kishnani PS, et al. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab. 2010;99(1):26–33.
13. Berrier KL, et al. CRIM-negative infantile Pompe disease: characterization of immune responses in patients treated with ERT monotherapy. Genet Med. 2015;17(11):912–918.
14. Lumizyme R [Package Insert]. Cambridge, MA: Genzyme Corporation, 2016.
15. Doerfler PA, Nayak S, Herzog RW, Morel L, Byrne BJ. BAFF blockade prevents anti-drug antibody formation in a mouse model of Pompe disease. Clin Immunol. 2015;158(2):140–147.
16. Ohashi T, et al. Administration of anti-CD3 antibodies modulates the immune response to an infusion of α-glucosidase in mice. MolTher. 2012;20(10):1924–1931.
17. Sun B, et al. Non-depleting anti-CD4 monoclonal antibody induces immune tolerance to ERT in a murine model of Pompe disease. Mol Genet Metab Rep. 2014;1:446–450.
18. Joly MS, et al. Transient low-dose methotrexate generates B regulatory cells that mediate antigen-specific tolerance to alglucosidase alfa. J Immunol. 2014;193(8):3947–3958.
19. Elder ME, et al. B-Cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr. 2013;163(3):847–54.e1.
20. Lim HH, et al. Immunomodulation to enzyme replacement therapy with tolerogenic nanoparticles containing rapamycin in a murine model of Pompe disease. Mol Genet Metab. 2017;120(1):S83–S84.
21. Mendelsohn NJ, Messinger YH, Rosenberg AS, Kishnani PS. Elimination of antibodies to recombinant enzyme in Pompe’s disease. N Engl J Med. 2009;360(2):194–195.
22. Messinger YH, et al. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet Med. 2012;14(1):135–142.
23. Banugaria SG, et al. Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile Pompe disease: a step towards improving the efficacy of ERT. PLoS One. 2013;8(6):e67052.
24. Banugaria SG, et al. Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease. Genet Med. 2013;15(2):123–131.
25. Kazi ZB, et al. Durable and sustained immune tolerance to ERT in Pompe disease with entrenched immune responses. JCI Insight. 2016;1(11):e86821.
26. Stenger EO, Kazi Z, Lisi E, Gambello MJ, Kishnani P. Immune tolerance strategies in siblings with infantile Pompe disease-advantages for a preemptive approach to high-sustained antibody titers. Mol Genet Metab Rep. 2015;4:30–34.
27. Kishnani PS, et al. Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction. Mol Genet Metab. 2016;117(2):66–83.
28. Bali DS, et al. Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience. Am J Med Genet C Semin Med Genet. 2012;160C(1):40–49.
29. Mutation in Human Acid Alpha-Glucosidase. The Erasmus University Medical Center. http://cluster15.erasmusmc.nl/klgn/pompe/mutations.html?lang=en. Updated May 2016. Accessed June 12, 2017.
30. GAA Mutation Database. Duke University. https://pediatrics.duke.edu/sites/pediatrics.duke.edu/files/field/attachments/GAA_mutation_database.pdf. Accessed June 12, 2017.
31. Vogel M, Staller W, Bühlmeyer K. Left ventricular myocardial mass determined by cross-sectional echocardiography in normal newborns, infants, and children. Pediatr Cardiol. 1991;12(3):143–149.
32. Prater SN, Banugaria SG, Morgan C, Sung CC, Rosenberg AS, Kishnani PS. Letter to the Editors: Concerning “CRIM-negative Pompe disease patients with satisfactory clinical outcomes on enzyme replacement therapy” by Al Khallaf et al. J Inherit Metab Dis. 2014;37(1):141–143.
33. Broomfield A, et al. Response of 33 UK patients with infantile-onset Pompe disease to enzyme replacement therapy. J Inherit Metab Dis. 2016;39(2):261–271.
34. França MM, Arnhold IJ. Clarification of intellectual abilities in patients with GLI2 mutations cited by Kevelam et al., 2012 Am J Med Genet Part A. Am J Med Genet A. 2012;158A(6):1519.
35. Khallaf HHA, Propst J, Geffrard S, Botha E, Pervaiz MA. CRIM-negative Pompe disease patients with satisfactory clinical outcomes on enzyme replacement therapy. JIMD Rep. 2013;9:133–137.
36. Rohrbach M, et al. CRIM-negative infantile Pompe disease: 42-month treatment outcome. J Inherit Metab Dis. 2010;33(6):751–757.
37. Rezvani AR, Maloney DG. Rituximab resistance. Best Pract Res Clin Haematol. 2011;24(2):203–216.
38. Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol. 2013;13(3):176–189.
39. Determination of cross-reactive immunological material (CRIM) status and longitudinal follow-up of individuals with Pompe disease; NCT01665326. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01665326. Accessed June 22, 2017.
40. Kishnani PS, et al. Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr Res. 2009;66(3):329–335.
41. Amalfitano A, et al. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med. 2001;3(2):132–138.
42. Young SP, et al. Long-term monitoring of patients with infantile-onset Pompe disease on enzyme replacement therapy using a urinary glucose tetrasaccharide biomarker. Genet Med. 2009;11(7):536–541.
43. Kaplan EL, Meier P. Nonparametric Estimation from Incomplete Observations. J Am Stat Assoc. 1958;53(282):457–481.